TG Therapeutics, Inc. (TGTX) earnings
TGTX earnings moved a median of +0.96% by the close. Quarterly and annual TGTX reports and results, each read against the price at its own news timestamp. Back to the TGTX overview →
31 measured TGTX earnings events.
Where these TGTX earnings landedvs 31 measured TGTX earnings reactions
| Middle 50% of TGTX earnings reactions | -1.32% to +4.18% |
|---|---|
| Median reaction (to close) | +0.96% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 TGTX earnings events with a measured close landed between -1.32% and +4.18%; 61% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q TG THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | +0.38% | -0.66% | |
| TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance | Press release | -2.94% | -9.33% | |
| TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update | Press release | -0.35% | -2.53% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +0.26% | +2.56% | |
| TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | +6.17% | +15.78% | |
| TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update | Press release | +0.27% | +0.60% | |
| Form 10-K TG THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +0.66% | +0.03% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | -0.38% | -1.98% | |
| TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | -9.53% | -7.19% | |
| TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update | Press release | +1.62% | +2.26% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | -1.97% | +0.96% | |
| TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | -1.83% | -10.64% | |
| TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update | Press release | -0.17% | +0.69% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +2.60% | +4.57% | |
| TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance | Press release | -2.24% | -5.21% | |
| TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update | Press release | +2.33% | +5.99% | |
| Form 10-K TG THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +3.15% | +3.49% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | -0.45% | +4.23% | |
| TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance | Press release | -2.03% | -0.25% | |
| TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update | Press release | +0.61% | +6.41% | |
| Form 10-K/A TG THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +2.77% | +2.89% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | +2.77% | +2.89% | |
| TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance | Press release | +0.03% | +7.92% | |
| TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update | Press release | -0.64% | -0.29% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +1.03% | +4.12% | |
| TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results | Press release | +1.42% | -7.41% | |
| TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update | Press release | +1.42% | -7.41% | |
| Form 10-K TG THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +0.74% | +2.40% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +0.19% | +4.94% | |
| TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results | Press release | +4.84% | -0.39% | |
| TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update | Press release | +3.21% | +5.57% |
Keep exploring
More TGTX: analyst actions → · SEC filings → · TGTX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| PROVECTUS BIOPHARMS (PVCT) | 220 | +0.01% | 50% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.